A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects (NCT07717749) | Clinical Trial Compass
Not Yet RecruitingPhase 1
A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects
South Korea74 participantsStarted 2026-07-24
Plain-language summary
A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects
Who can participate
Age range
19 Years – 64 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
* Subjects aged 19 years or older and under 65 years at the screening visit
Exclusion Criteria:
* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
* Other exclusions applied
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is a Phase 1 trial testing AD-118 and AD-1181 for the first time in humans, what does that mean for what we'd know — or not know — about whether it actually helps with my chronic heart failure at this stage?
2This study is listed as 'not yet recruiting,' so is it worth tracking for when it opens, or are there other trials or standard treatments I should be considering right now while I wait?
3The trial is focused on measuring how the drug moves through the bloodstream — things like peak concentration and how long it stays in the body — rather than whether it improves heart failure symptoms, so should I have realistic expectations that this study isn't designed to show me any direct health benefit?
4Since this is an early-stage safety study in healthy adults rather than people with chronic heart failure, does that mean someone with my specific condition and health history would even be a candidate when it does open, or could my heart failure itself disqualify me?
5Given that Phase 1 trials are primarily about safety and dosing, what kinds of side effects or risks are generally being watched for with new heart-related compounds, and how would my current heart failure status affect my ability to handle any unexpected reactions?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Area under the plasma concentration-time curve during dosing interval (AUCt)
Timeframe: [Time Frame: pre-dose (0hour) to 36hours]
2
Maximum concentration of drug in plasma (Cmax)
Timeframe: Time Frame: pre-dose (0hour) to 36hours]